TY - JOUR
T1 - Ischemic brain injury
T2 - A consortium analysis of key factors involved in mesenchymal stem cell-mediated inflammatory reduction
AU - McGuckin, Colin P.
AU - Jurga, Marcin
AU - Miller, Anne Marie
AU - Sarnowska, Anna
AU - Wiedner, Marc
AU - Boyle, Noreen T.
AU - Lynch, Marina A.
AU - Jablonska, Anna
AU - Drela, Katarzyna
AU - Lukomska, Barbara
AU - Domanska-Janik, Krystyna
AU - Kenner, Lukas
AU - Moriggl, Richard
AU - Degoul, Olivier
AU - Perruisseau-Carrier, Claire
AU - Forraz, Nico
N1 - Funding Information:
The overall consortium was funded by the Novus Sanguis fund , jointly created by McGuckin, Forraz and Fondation LeJeune (Paris) , to whom we thank. The work was also supported by grant Sonderforschungsbereich (SFB F28) of the Austrian Science Foundation (FWF) to Richard Moriggl. Lukas Kenner was also supported by Fonds zur Förderung der wissenschaftlichen Forschung ( P-18478-B12 ) and Genome Research-Austria project “Inflammobiota”. We are particularly grateful to obstetrics and gynaecology staff of Hopital St. Joseph-St. Luc., Lyon, France; Hopital Natecia, Lyon, (France) for essential collection and supply of human clinical samples for this research study.
Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2013/6
Y1 - 2013/6
N2 - Increasing global birth rate, coupled with the aging population surviving into their eighth decade has lead to increased incidence diseases, hitherto designated as rare. Brain related ischemia, at birth, or later in life, during, for example stroke, is increasing in global prevalence. Reactive microglia can contribute to neuronal damage as well as compromising transplantion. One potential treatment strategy is cellular therapy, using mesenchymal stem cells (hMSCs), which possess immunomodulatory and cell repair properties. For effective clinical therapy, mechanisms of action must be understood better. Here multicentre international laboratories assessed this question together investigating application of hMSCs neural involvement, with interest in the role of reactive microglia. Modulation by hMSCs in our in vivo and in vitro study shows they decrease markers of microglial activation (lower ED1 and Iba) and astrogliosis (lower GFAP) following transplantation in an ouabain-induced brain ischemia rat model and in organotypic hippocampal cultures. The anti-inflammatory effect in vitro was demonstrated to be CD200 ligand dependent with ligand expression shown to be increased by IL-4 stimulation. hMSC transplant reduced rat microglial STAT3 gene expression and reduced activation of Y705 phosphorylated STAT3, but STAT3 in the hMSCs themselves was elevated upon grafting. Surprisingly, activity was dependent on heterodimerisation with STAT1 activated by IL-4 and Oncostatin M. Our study paves the way to preclinical stages of a clinical trial with hMSC, and suggests a non-canonical JAK-STAT signaling of unphosphorylated STAT3 in immunomodulatory effects of hMSCs.
AB - Increasing global birth rate, coupled with the aging population surviving into their eighth decade has lead to increased incidence diseases, hitherto designated as rare. Brain related ischemia, at birth, or later in life, during, for example stroke, is increasing in global prevalence. Reactive microglia can contribute to neuronal damage as well as compromising transplantion. One potential treatment strategy is cellular therapy, using mesenchymal stem cells (hMSCs), which possess immunomodulatory and cell repair properties. For effective clinical therapy, mechanisms of action must be understood better. Here multicentre international laboratories assessed this question together investigating application of hMSCs neural involvement, with interest in the role of reactive microglia. Modulation by hMSCs in our in vivo and in vitro study shows they decrease markers of microglial activation (lower ED1 and Iba) and astrogliosis (lower GFAP) following transplantation in an ouabain-induced brain ischemia rat model and in organotypic hippocampal cultures. The anti-inflammatory effect in vitro was demonstrated to be CD200 ligand dependent with ligand expression shown to be increased by IL-4 stimulation. hMSC transplant reduced rat microglial STAT3 gene expression and reduced activation of Y705 phosphorylated STAT3, but STAT3 in the hMSCs themselves was elevated upon grafting. Surprisingly, activity was dependent on heterodimerisation with STAT1 activated by IL-4 and Oncostatin M. Our study paves the way to preclinical stages of a clinical trial with hMSC, and suggests a non-canonical JAK-STAT signaling of unphosphorylated STAT3 in immunomodulatory effects of hMSCs.
KW - Inflammation
KW - Ischemia
KW - JAK-STAT signaling
KW - Mesenchymal stem cells
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=84876818519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876818519&partnerID=8YFLogxK
U2 - 10.1016/j.abb.2013.02.005
DO - 10.1016/j.abb.2013.02.005
M3 - Article
C2 - 23466243
AN - SCOPUS:84876818519
SN - 0003-9861
VL - 534
SP - 88
EP - 97
JO - Archives of Biochemistry and Biophysics
JF - Archives of Biochemistry and Biophysics
IS - 1-2
ER -